Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
about
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidenceAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlIncretin-Based Therapy for Prevention of Diabetic Vascular ComplicationsNephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Targeting inflammation in diabetes: Newer therapeutic optionsBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesPathophysiology of Non Alcoholic Fatty Liver DiseaseGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeGlucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expressionClinical therapeutic strategies for early stage of diabetic kidney disease.Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus.Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.The stem cell adjuvant with Exendin-4 repairs the heart after myocardial infarction via STAT3 activation.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemDPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese ratEffects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationDipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin.Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in MiceSuppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis.Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- MiceProtective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetesPhysical exercise, fasting glucose, and renal hyperfiltration in the general population: the Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6).Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in MiceGLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy.Implications of treatment that target protective mechanisms against diabetic nephropathyThe endothelium in diabetes: its role in insulin access and diabetic complicationsSynergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood-Retinal Barrier Breakdown and InflammationAcute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trialRenoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome.
P2860
Q26739999-DF780E64-4771-43E9-814B-63500CBEDE27Q26750746-72417966-3D41-4CAC-92CF-C17F388CCE6EQ26765470-DE37B597-3A87-47C8-A4EE-EE31C2A6D730Q26777994-620C24B5-0E22-4349-B705-1859807D2E4DQ26852726-664A800E-5679-4E88-8F80-776108E72626Q27010669-B2121B27-02FA-492D-9A05-070F8CB43C51Q28067465-A3A5911B-2DFA-45DC-B03E-74D2C27DD71BQ28070011-37964A76-2209-429E-A5F1-776012D4DA3AQ28070416-D9444C2F-4F12-44CA-9518-EAB323E5D6B8Q28570190-884C7736-FC95-4AF4-B294-F635C682EE53Q30363683-A2F80B76-D5DB-4381-9418-3CFE16FBE9BCQ33603384-89D733EA-C404-40D5-B698-01B9C14D9732Q33607642-B3B40AA3-BE84-45A7-9F11-A05B1425BE17Q33608090-281A3BF8-221A-4CE4-8F74-059428175032Q33610654-EFE8C2AF-7DD4-43E6-9CD1-4246A9552D6AQ34011497-EEB6CE99-A2ED-4B1C-8B7F-00D2BE716F3BQ34062829-A277185A-A73C-4C73-93D3-9D84A3D1919BQ34270500-085CE38B-5225-4FCA-A5B5-0D5A25B17EA2Q34405101-16E0043A-9493-42B3-B54D-61D93F33FA65Q34690495-D466E8B8-5311-4A0D-8217-5E3C67983A1EQ35194026-53362D22-16C5-491D-B717-277208693FDFQ35201564-223C3A57-1562-4FAA-ADA7-65AB40AD28CBQ35285238-81C71475-2157-4B8F-ABD5-61D21136C948Q35857721-910DBA77-C9C0-453A-B037-774AB96C5DB0Q36035037-A4F9781E-F7DB-44E3-BADD-821E67061FCEQ36101582-57EEC1CD-51EA-41C6-8394-7D838E5A2E64Q36224740-CCD5CA29-C813-4ECF-A6A0-BC543323AAFCQ36228307-CEEC807F-1F5F-4202-AA1F-30F01ED0D2E4Q36339470-893A7F55-4526-47BF-A3BA-D1C284D33A3CQ36371075-03569894-D4DB-4356-8B5D-0BFBF0B86F97Q36382309-EB3DE376-27E4-46A0-9610-E4D5D8060AA7Q36406821-6F3F107A-9137-4F01-B284-787052385AD9Q36550886-BD0512B9-8717-40B9-BEED-EBAA9D776698Q36645971-7368F3B8-66E4-44A1-AE74-25C3105D93E8Q36672866-CC589F0A-D2F2-4403-920E-434D5B1767C1Q36859559-2E4DBD9F-43B9-4EE8-8CD4-D4EE8A99C18BQ36904161-D8BBC168-1B1D-4D39-8EA7-D56DF4B65D6BQ36990093-6A501FC9-0185-4968-B5DA-73A1E1CFD9E2Q37056839-5843CD8D-53D2-4549-8C4E-320A0DCEB30EQ37177528-023D34DE-0AE6-4DE3-802D-1A7DA8F2A019
P2860
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@en
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@nl
type
label
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@en
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@nl
prefLabel
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@en
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@nl
P2093
P2860
P921
P1433
P1476
Glucagon-like peptide-1 recept ...... rat model of type 1 diabetes.
@en
P2093
H U Kataoka
N Kajitani
P2860
P2888
P304
P356
10.1007/S00125-010-2028-X
P577
2011-01-21T00:00:00Z